Nanalysis Scientific Corp. Logo

Nanalysis Scientific Corp.

NSCIF

(1.2)
Stock Price

0,22 USD

-42.6% ROA

-34.52% ROE

-3.6x PER

Market Cap.

46.531.118,74 USD

64.42% DER

0% Yield

-19.26% NPM

Nanalysis Scientific Corp. Stock Analysis

Nanalysis Scientific Corp. Fundamental Analysis

Fundamental analysis in stock investing is like studying the foundation of a house before buying it. It involves looking at a company's financial health, like its earnings, assets, and debts, to determine if it's a good investment based on its fundamental strength and potential for growth.

Nanalysis Scientific Corp. Fundamental Stock Analysis
# Analysis Rating
1 Assets Growth

With continuous growth in revenue over the last five years, this company has proven to be a lucrative investment option, showcasing its strong financial performance.

2 PBV

The stock's PBV ratio (1.36x) indicates a justifiable valuation, presenting a compelling choice for investors seeking reasonable returns.

3 DER

The stock maintains a fair debt to equity ratio (58%), indicating a reasonable balance between the money it owes and the ownership it possesses.

4 Graham Number

The Graham number analysis indicates that this company's stock price is likely undervalued, raising prospects for a favorable investment opportunity.

5 ROE

Negative ROE (-41.5%) indicates poor financial performance, raising concerns about profitability and efficiency in utilizing shareholders' equity.

6 ROA

The stock's ROA (-44.26%) indicates that it's not effectively utilizing its assets to generate profits, making it a less favorable option to invest and earn consistent returns.

7 Revenue Growth

Company has experienced no growth in revenue over the past three years, suggesting limited profitability and making it a less desirable investment opportunity.

8 Net Profit Growth

The net profit of this company has shown no signs of growth over the last five years, suggesting limited profitability and making it a less attractive investment opportunity.

9 Dividend Growth

Potential investors should be aware that the company's dividend growth has shown no upward trend in the past three years, indicating limited potential for increased returns.

10 Dividend

Investors should be cautious as the company hasn't distributed dividends in the last three years, possibly indicating financial challenges.

11 Buffet Intrinsic Value

The company's stock appears overvalued (-1) by Warren Buffett's formula, suggesting a less favorable investment opportunity as its market price exceeds its estimated intrinsic value.

Nanalysis Scientific Corp. Technical Analysis

Technical analysis in stock investing is like reading the patterns on a weather map to predict future weather conditions. It involves studying past stock price movements and trading volumes to make predictions about where a stock's price might go next, without necessarily looking at the company's financial health.

Nanalysis Scientific Corp. Technical Stock Analysis
# Analysis Recommendation
1 Awesome Oscillator Hold
2 MACD Buy
3 RSI Hold
4 Stoch RSI Hold

Nanalysis Scientific Corp. Price Chart

Financial Statements

Financial statements are like report cards for companies. They show how much money a company makes (income statement), what it owns and owes (balance sheet), and where it spends its money (cash flow statement), helping stock investors understand if a company is healthy and worth investing in.

Income Statements

An income statement for a company is like a scoreboard for its profits and losses. It shows how much money the company made (revenue) and how much it spent to make that money (expenses), helping stock investors see if a company is making a profit or not.

Revenue in stock investing is the total amount of money a company earns from its sales, and it's a key factor that investors consider to assess a company's financial performance and growth potential.

Nanalysis Scientific Corp. Revenue
Year Revenue Growth
2016 5.251.843
2017 7.668.298 31.51%
2018 8.381.000 8.5%
2019 8.364.000 -0.2%
2020 7.874.000 -6.22%
2021 16.043.000 50.92%
2022 24.821.000 35.37%
2023 28.144.000 11.81%
2023 28.466.000 1.13%
2024 45.896.000 37.98%

Research and Development Expenses are the costs a company incurs to create and improve its products or services, which can be important for investors to evaluate a company's innovation and potential for future growth.

Nanalysis Scientific Corp. Research and Development Expenses
Year Research and Development Expenses Growth
2016 0
2017 0 0%
2018 166.000 100%
2019 270.000 38.52%
2020 476.000 43.28%
2021 643.000 25.97%
2022 1.465.000 56.11%
2023 792.000 -84.97%
2023 679.000 -16.64%
2024 52.000 -1205.77%

General and Administrative Expenses are the costs a company incurs to run its day-to-day operations, such as office rent, salaries, and utilities, which investors consider to understand a company's overall efficiency and management effectiveness.

Nanalysis Scientific Corp. General and Administrative Expenses
Year General and Administrative Expenses Growth
2016 1.325.443
2017 1.315.059 -0.79%
2018 2.256.000 41.71%
2019 2.766.000 18.44%
2020 3.512.000 21.24%
2021 6.140.000 42.8%
2022 12.665.000 51.52%
2023 11.316.000 -11.92%
2023 11.041.000 -2.49%
2024 10.976.000 -0.59%

EBITDA stands for Earnings Before Interest, Taxes, Depreciation, and Amortization. It is a measure that helps stock investors analyze a company's profitability by looking at its earnings without considering certain expenses. This helps to get a clearer picture of the company's financial performance and its ability to generate cash flow.

Nanalysis Scientific Corp. EBITDA
Year EBITDA Growth
2016 -25.250
2017 -173.330 85.43%
2018 695.000 124.94%
2019 2.435.000 71.46%
2020 -1.409.000 272.82%
2021 1.959.000 171.92%
2022 -4.848.000 140.41%
2023 -7.324.000 33.81%
2023 -8.869.000 17.42%
2024 380.000 2433.95%

Gross profit is the money a company makes from selling its products or services after subtracting the cost of producing or providing them, and it is an important measure for investors to understand a company's profitability.

Nanalysis Scientific Corp. Gross Profit
Year Gross Profit Growth
2016 3.104.930
2017 4.894.710 36.57%
2018 5.398.000 9.32%
2019 6.060.000 10.92%
2020 5.167.000 -17.28%
2021 10.240.000 49.54%
2022 11.139.000 8.07%
2023 6.504.000 -71.26%
2023 -442.000 1571.49%
2024 8.520.000 105.19%

Net income in stock investing is like the money a company actually gets to keep as profit after paying all its bills, and it's an important measure to understand how well a company is doing financially.

Nanalysis Scientific Corp. Net Profit
Year Net Profit Growth
2016 -25.275
2017 -172.109 85.31%
2018 74.000 332.58%
2019 -1.660.000 104.46%
2020 -3.678.000 54.87%
2021 -2.353.000 -56.31%
2022 -9.915.000 76.27%
2023 -25.148.000 60.57%
2023 -16.196.000 -55.27%
2024 -7.980.000 -102.96%

EPS, or earnings per share, is a measure that shows how much profit a company has earned for each outstanding share of its stock, and it is important for stock investors as it helps understand the profitability of a company and compare it with other companies in the market.

Nanalysis Scientific Corp. Earning per Share (EPS)
Year Earning per Share (EPS) Growth
2016 0
2017 0 0%
2018 0 0%
2019 0 0%
2020 0 0%
2021 0 0%
2022 0 0%
2023 0 0%
2023 0 0%
2024 0 0%

Cashflow Statements

Cashflow statements show the movement of money in and out of a company, helping stock investors understand how much money a company makes and spends. By examining cashflow statements, investors can assess if a company is generating enough cash to pay its bills, invest in growth, and provide returns to stockholders.

Free cash flow is the leftover cash that a company generates after covering its operating expenses and capital expenditures, which is important for stock investors as it shows how much money a company has available to invest in growth, pay dividends, or reduce debt.

Nanalysis Scientific Corp. Free Cashflow
Year Free Cashflow Growth
2016 -616.732
2017 -188.716 -226.8%
2018 -2.419.000 92.2%
2019 -2.358.000 -2.59%
2020 -3.524.000 33.09%
2021 -4.203.000 16.16%
2022 -15.556.000 72.98%
2023 -16.061.000 3.14%
2023 -2.154.000 -645.64%
2024 256.000 941.41%

Operating cash flow represents the cash generated or consumed by a company's day-to-day operations, excluding external investing or financing activities, and is crucial for stock investors as it shows how much cash a company is generating from its core business operations.

Nanalysis Scientific Corp. Operating Cashflow
Year Operating Cashflow Growth
2016 -28.826
2017 -58.053 50.35%
2018 -171.000 66.05%
2019 781.000 121.9%
2020 -623.000 225.36%
2021 -1.199.000 48.04%
2022 -8.355.000 85.65%
2023 -11.469.000 27.15%
2023 -1.550.000 -639.94%
2024 757.000 304.76%

Capex, short for capital expenditures, refers to the money a company spends on acquiring or upgrading tangible assets like buildings, equipment, or technology, which is important for stock investors as it indicates how much a company is investing in its infrastructure to support future growth and profitability.

Nanalysis Scientific Corp. Capital Expenditure
Year Capital Expenditure Growth
2016 587.906
2017 130.663 -349.94%
2018 2.248.000 94.19%
2019 3.139.000 28.38%
2020 2.901.000 -8.2%
2021 3.004.000 3.43%
2022 7.201.000 58.28%
2023 4.592.000 -56.82%
2023 604.000 -660.26%
2024 501.000 -20.56%

Balance Sheet

Balance sheets provide a snapshot of a company's financial health and its assets (such as cash, inventory, and property) and liabilities (like debts and obligations) at a specific point in time. For stock investors, balance sheets help assess the company's overall worth and evaluate its ability to meet financial obligations and support future growth.

Equity refers to the ownership interest or stake that shareholders have in a company, representing their claim on its assets and earnings after all debts and liabilities are paid.

Nanalysis Scientific Corp. Equity
Year Equity Growth
2016 75.225
2017 631.179 88.08%
2018 8.391.000 92.48%
2019 15.119.000 44.5%
2020 14.344.000 -5.4%
2021 23.961.000 40.14%
2022 47.572.000 49.63%
2023 25.400.000 -87.29%
2023 23.481.000 -8.17%
2024 24.165.000 2.83%

Assets represent the valuable resources that a company owns, such as cash, inventory, property, and equipment, and understanding a company's assets helps investors assess its value and potential for generating future profits.

Nanalysis Scientific Corp. Assets
Year Assets Growth
2016 79.355
2017 690.677 88.51%
2018 10.948.000 93.69%
2019 18.306.000 40.19%
2020 23.989.000 23.69%
2021 37.793.000 36.53%
2022 69.902.000 45.93%
2023 52.579.000 -32.95%
2023 53.824.000 2.31%
2024 51.452.000 -4.61%

Liabilities refer to the financial obligations or debts that a company owes to creditors or external parties, and understanding a company's liabilities is important for investors as it helps assess the company's financial risk and ability to meet its obligations.

Nanalysis Scientific Corp. Liabilities
Year Liabilities Growth
2016 4.130
2017 59.498 93.06%
2018 2.557.000 97.67%
2019 3.187.000 19.77%
2020 9.645.000 66.96%
2021 13.832.000 30.27%
2022 22.330.000 38.06%
2023 27.179.000 17.84%
2023 30.343.000 10.43%
2024 27.287.000 -11.2%

Nanalysis Scientific Corp. Financial Ratio (TTM)

Valuation Metrics

Revenue per Share
0.35
Net Income per Share
-0.11
Price to Earning Ratio
-3.6x
Price To Sales Ratio
1.18x
POCF Ratio
-22.58
PFCF Ratio
-10.12
Price to Book Ratio
1.92
EV to Sales
1.59
EV Over EBITDA
-19.43
EV to Operating CashFlow
-30.47
EV to FreeCashFlow
-13.64
Earnings Yield
-0.28
FreeCashFlow Yield
-0.1
Market Cap
0,05 Bil.
Enterprise Value
0,06 Bil.
Graham Number
0.74
Graham NetNet
-0.15

Income Statement Metrics

Net Income per Share
-0.11
Income Quality
0.16
ROE
-0.52
Return On Assets
-0.17
Return On Capital Employed
-0.1
Net Income per EBT
1.21
EBT Per Ebit
1.85
Ebit per Revenue
-0.09
Effective Tax Rate
-0.14

Margins

Sales, General, & Administrative to Revenue
0.26
Research & Developement to Revenue
0.01
Stock Based Compensation to Revenue
0.03
Gross Profit Margin
0.19
Operating Profit Margin
-0.09
Pretax Profit Margin
-0.16
Net Profit Margin
-0.19

Dividends

Dividend Yield
0
Dividend Yield %
0
Payout Ratio
0
Dividend Per Share
0

Operating Metrics

Operating Cashflow per Share
-0.02
Free CashFlow per Share
-0.04
Capex to Operating CashFlow
-1.23
Capex to Revenue
0.06
Capex to Depreciation
0.56
Return on Invested Capital
-0.21
Return on Tangible Assets
-0.43
Days Sales Outstanding
90.57
Days Payables Outstanding
74.26
Days of Inventory on Hand
51.71
Receivables Turnover
4.03
Payables Turnover
4.91
Inventory Turnover
7.06
Capex per Share
0.02

Balance Sheet

Cash per Share
0,01
Book Value per Share
0,21
Tangible Book Value per Share
0.03
Shareholders Equity per Share
0.21
Interest Debt per Share
0.15
Debt to Equity
0.64
Debt to Assets
0.3
Net Debt to EBITDA
-5.02
Current Ratio
1.42
Tangible Asset Value
0,00 Bil.
Net Current Asset Value
-0,01 Bil.
Invested Capital
30406000
Working Capital
0,01 Bil.
Intangibles to Total Assets
0.41
Average Receivables
0,01 Bil.
Average Payables
0,01 Bil.
Average Inventory
4806500
Debt to Market Cap
0.33

Dividends

Dividends in stock investing are like rewards that companies give to their shareholders. They are a portion of the company's profits distributed to investors, typically in the form of cash payments, as a way for them to share in the company's success.

Nanalysis Scientific Corp. Dividends
Year Dividends Growth

Nanalysis Scientific Corp. Profile

About Nanalysis Scientific Corp.

Nanalysis Scientific Corp., develops, manufactures, and sells compact nuclear magnetic resonance (NMR) spectrometers and magnetic resonance imaging equipment for the pharmaceutical, biotech, chemical, security, food, materials, and education industries. It operates through three segments: Nanalysis, RS2D, and Corporate. The company also offers software module packages; manufactures and sells cutting-edge electronics components for precision analytical instruments; and provides monitoring and supporting services for its NMR technologies. It sells its products directly, as well as through a network of distributors worldwide. The company is headquartered in Calgary, Canada.

CEO
Mr. Sean Krakiwsky M.Sc.
Employee
249
Address
Bay 1, 4600 5th Street NE
Calgary, T2E 7C3

Nanalysis Scientific Corp. Executives & BODs

Nanalysis Scientific Corp. Executives & BODs
# Name Age
1 Mr. Sean Krakiwsky M.Sc.
Founder, Chief Executive Officer, President & Director
70
2 Mr. Randall McRae C.A., CPA
Corporate Controller & Chief Financial Officer
70
3 Mr. Matthew Selinger
Investor Relations Manager
70
4 Mr. Nick MacKenzie
Vice President of Sales
70
5 Mr. Sime Buric
Executive Vice President of Services
70
6 Dr. Greg McFeetors
Head of Manufacturing
70
7 Mr. Martin Andrew Burian C.A., CPA
Corporate Secretary & Independent Chairman
70
8 Dr. Heather Phillips
Vice President of Operations
70
9 Dr. Susanne Riegel
Vice President of Marketing & Product Manager
70
10 Mr. Julien Muller
Chief Technology Officer
70

Nanalysis Scientific Corp. Competitors